NCT00005618View on ClinicalTrials.gov

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 29, 2000

Study Completion Date

March 31, 2004

Conditions
Leukemia
Interventions
DRUG

arsenic trioxide

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00005618 - Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter